Dementia: Is new drug a major breakthrough?
LMTX slows Alzheimer's progression - but it doesn't work on everyone and experts are urging caution

A new drug appears to slow down the progression of Alzheimer's disease – but only in certain cases.
Some scientists have hailed the results of the trial as a major breakthrough in a field that has seen little advancement in decades, but others are far more sceptical.
What is it and how does it work?
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
LMTX is taken twice a day in tablet form. In the trial, it was used to treat 891 patients with mild to moderate Alzheimer's for 18 months, with the results presented at a conference in Toronto, Canada.
It is the first time a major drug trial has targeted tau tangles – abnormal clumps of protein that disrupt brain function – instead of beta-amyloid, a different type of protein that forms plaques as it accumulates in the brain, the New Scientist reports.
"The success of the LMTX trial suggests that tau tangles might be the main cause of Alzheimer's symptoms," it says.
How successful is it?
Overall, the trial was a flop as there appeared to be no benefit to taking LMTX, says the BBC's health and science correspondent, James Gallagher.
"However, an analysis on just the 15 per cent of the patients who had not already been taking drugs to help manage their symptoms showed a benefit," he adds. "In this tiny subset of patients, tests showed thinking power was maintained and MRI scans found the death of brain cells was reduced."
Claude Wischik, the co-founder of TauRx Pharmaceuticals, which developed the drug, said the results were unprecedented. "On the whole, [it] slowed progression by about 80 per cent," he says.
Though further testing is needed, LMTX has helped people get back to their daily lives, he says: "A wife of a patient told me her husband suddenly got up and fixed the garden fence, which he'd needed to do for years."
What has the reaction been?
The discovery was hailed by many, with the US Alzheimer's Association describing it as "a significant event" in the history of dementia research.
"In a field that has been plagued by consistent failures of novel drug candidates in late-stage clinical trials and where there has been no practical therapeutic advance for over a decade, I am excited," said Dr Serge Gauthier, the director of the Alzheimer's Disease Research Unit at McGill University, Canada.
Others, however, have urged caution. Alzheimer's Research UK's Dr David Reynolds said he was concerned LMTX appeared not to work alongside other medications.
"The data suggests it is slowing down the disease, but the important caveat is these small numbers," he said.
"It is encouraging, but we need more data and will have to run a study with it as just a monotherapy [on its own]," he added. "It will still be years from reaching patients, even assuming it works."
Dr Rachelle Doody, the director of the Alzheimer's disease and Memory Disorders Center at Baylor College of Medicine in Texas, was even more pessimistic. "To present it to the public now as a promising approach seems unjustified," she told the New York Times.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Today's political cartoons - March 30, 2025
Cartoons Sunday's cartoons - strawberry fields forever, secret files, and more
By The Week US Published
-
5 hilariously sparse cartoons about further DOGE cuts
Cartoons Artists take on free audits, report cards, and more
By The Week US Published
-
Following the Tea Horse Road in China
The Week Recommends This network of roads and trails served as vital trading routes
By The Week UK Published
-
'Like a sound from hell': Serbia and sonic weapons
The Explainer Half a million people sign petition alleging Serbian police used an illegal 'sound cannon' to disrupt anti-government protests
By Abby Wilson Published
-
The arrest of the Philippines' former president leaves the country's drug war in disarray
In the Spotlight Rodrigo Duterte was arrested by the ICC earlier this month
By Justin Klawans, The Week US Published
-
Ukrainian election: who could replace Zelenskyy?
The Explainer Donald Trump's 'dictator' jibe raises pressure on Ukraine to the polls while the country is under martial law
By Sorcha Bradley, The Week UK Published
-
Why Serbian protesters set off smoke bombs in parliament
THE EXPLAINER Ongoing anti-corruption protests erupted into full view this week as Serbian protesters threw the country's legislature into chaos
By Rafi Schwartz, The Week US Published
-
Who is the Hat Man? 'Shadow people' and sleep paralysis
In Depth 'Sleep demons' have plagued our dreams throughout the centuries, but the explanation could be medical
By The Week Staff Published
-
Why Assad fell so fast
The Explainer The newly liberated Syria is in an incredibly precarious position, but it's too soon to succumb to defeatist gloom
By The Week UK Published
-
Romania's election rerun
The Explainer Shock result of presidential election has been annulled following allegations of Russian interference
By Sorcha Bradley, The Week UK Published
-
Russia's shadow war in Europe
Talking Point Steering clear of open conflict, Moscow is slowly ratcheting up the pressure on Nato rivals to see what it can get away with.
By The Week UK Published